

Modeling the SARS-CoV-2 Epidemic and the Efficacy of Different Vaccines Across Different Network Structures

Hartvigsen, Gregg¹, and Yannis Dimitroff

¹Contact: hartvig@geneseo.edu

1 Abstract

We developed a network-based SEIRV model to test different vaccine efficacies on SARS-CoV-2 dynamics in a naive population of 25,000 susceptible adults. Different vaccine efficacies, derived from data, were administered at different rates across a range of different Watts-Strogatz network structures. The model suggests that differences among vaccines were of minor importance compared to vaccination rates and network structure. Additionally, we tested the effect of strain differences in transmissibility (R_0 values of 2.5 and 5.0) and found that this was the most important factor influencing the number of individuals ultimately infected. However, network structure was most important in affecting the maximum number of individuals that were infectious during the epidemic peak. The interaction of network structure, vaccination effort, and difference in strain transmissibility was highly significant for all epidemic metrics. The model suggests that differences in vaccine efficacy are not as important as vaccination rate in reducing epidemic sizes. Further, the importance of the evolution of viral transmission rates and our ability to develop effective vaccines to combat these strains will be of primary concern for our ability to control future disease epidemics.

2 Introduction

Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) began spreading through the human population at the end of 2019. The virus is highly infectious and continues to spread through the population after having caused widespread morbidity, mortality, and disruptions of basic human activities worldwide (e.g., WHO, 2020). A multinational effort with multiple pharmaceutical companies led to the production of several vaccines. An additional challenge was that vaccines were not made available equitably across nations. The challenge remains as to determine the efficacy of different vaccines with multiple doses to increase immune response. Additionally, vaccine hesitancy remains a challenge nearly everywhere (Steinert et al., 2022).

The different SARS-CoV-2 vaccines exhibit different efficacies in stimulating immunity (IHME, 2021). Additionally, data suggest that individuals respond differently to these vaccines but that all vaccines reduce the levels of morbidity, mortality, and the rates of hospitalizations (Rahmani et al., 2022; de Gier et al., 2023; Link-Gelles et al., 2024). Various clinical trials also have differed in their target audiences which helps to explain why efficacies vary (IHME, 2021). Additionally, effectiveness varies among patients based on underlying health risks (Banerjee et al., 2020). Unfortunately, clinical trials also usually only assess disease expression rather than the likelihood that individuals can spread of the disease agent (Perkins et al., 2019).

An important question remains as to whether vaccines for SARS-CoV-2 or other disease agents, with their different efficacies, lead to different rates or morbidity, especially when populations may be exhibiting different levels of connectivity (e.g., visiting only with family members or interacting with individuals throughout a community). It has been shown that different efficacies of a first vaccine dose may be of less importance if individuals receive a second dose of a vaccine (Saad-Roy et al., 2021). Additionally, reducing transmission can lead to an increase in virulence by favoring agents with higher growth rates (Gandon et al., 2001). In this paper we test the effects of employing vaccines with a range of efficacies that were found in the range of the early vaccines that were administered and test the effectiveness of one dose versus the addition of a second booster dose. However, to match the fact that vaccines are imperfect, we assume vaccine efficacy never reaches 100% (El Sahly et al., 2021). Additionally, it's important to note that we assume vaccinated individuals are less likely to transmit the virus to neighbors, that all individuals have equal responses to vaccines, and that immune responses to infection are homogeneous.

During the early days of the SARS-CoV-2, daily vaccine rates in the United States ranged from 1-4 million individuals per day, or approximated 0.301 to 1.205% per day, assuming a population of 332 million

individuals. Unfortunately, early stages of vaccinations in most countries (e.g., USA and England) withheld vaccinating young individuals who also are more likely to be asymptomatic spreaders (Yonker et al., 2020). More troubling, however, is that the daily delivery of doses declined (CDC, 2021a). We, therefore, investigate the effects of vaccinating populations over a range of daily delivery rates.

In this paper we simulate the emergence of SARS-CoV-2 in a naive population and test how deploying vaccines with different efficacies, and the rate of deployment of either one or two doses, affects disease spread. We investigate several response variables that assess the extent of the epidemic. These include the number of individuals infected, the duration of the epidemic, the maximum number of individuals infectious (epidemic peak), and the day this maximum occurs. Reducing the epidemic peak size, often referred to as working to “flatten the curve,” is critical for health care systems to be able to accommodate the affected population before they become overloaded.

The primary goal of this work is to help us to gain greater insight into the emergence of new viral disease agents and what responses can be implemented so as to reduce the rates of morbidity and to help inform vaccine deployment under a variety of conditions.

3 Methods

We developed an SEIRV epidemiological model (figure 1) that runs on a Watts-Strogatz (1998) small-world network using five differently structured networks. Populations of 25,000 susceptible individuals were connected with 125,000 edges ($k = 10$). Our model assumes that all individuals are equally susceptible to viral infection. However, we recognize that individuals may gain some protection from prior exposures to endemic human coronaviruses (Kundu et al., 2022). Each run began by creating a new small-world network with one of five rewiring parameter values (see table 1). To begin, six randomly chosen individuals were inoculated with an agent simulating SARS-CoV-2 virus with three individuals being in the exposed class (E) and three in the infectious class (I). The five different small-world network structures were created using the rewiring parameter (P) with networks that ranged from nearly structured as a regular circulant ($P = 0.004$) to a relatively random network ($P = 0.5$, see table 1). These particular network structures were chosen based on the responses of disease dynamics across the range of possible networks (see figure 2). We chose the Watts-Strogatz structure for its properties that allow us to test quite different networks while maintaining a constant number of edges and, therefore, an identical median degree.

The advantage of this family of networks is that we can simulate population structures across a range of clustering coefficients and average path lengths using the single parameter P while holding the number of vertices and edges constant. Therefore, responses we see with different values of P are due to how individuals are connected in the network. Edges in these networks are undirected and represent possible transmission routes for the SARS-CoV-2 virus among individuals. For comparison we can see that the degree distributions of the five networks are quite different (figure 3).




Figure 1: The structure of the SEIRV model. Compartments represent states of individuals, being either susceptible (S), exposed (E), infectious (I), recovered (R), or individuals that have received the first (V_1) or second (V_2) dose of the vaccine. Solid arrows indicate the possible movement of individuals from one compartment to another. Susceptible individuals move into the exposed class with probability T for each of their neighbors that are infectious (dashed arrows; see equation 1). Unvaccinated individuals in the S , E , or R states are randomly chosen to be vaccinated. Individuals move deterministically from $E \rightarrow I$, $I \rightarrow R$, and $V_1 \rightarrow V_2$.

It is made available under a [CC-BY-NC-ND 4.0 International license](https://creativecommons.org/licenses/by-nc-nd/4.0/).




Figure 2: Model sensitivity to network structure in the COVID-19 model without vaccination. Network structure is controlled by the parameter P , which is the proportion of edges that are randomly chosen, disconnected, and then reconnected to a randomly chosen individual in the population (see Watts and Strogatz, 1998). The red vertical bars represent the five network structures used in the simulations (see table 1). Note the responses for the total number infected (upper left) rises quickly at about $P = 0.004$. Additionally, average epidemic duration (upper right) and the average day that the epidemic has the highest prevalence (lower right) are greatest at this level of rewiring. All simulations were run with $N = 25,000$ and $k = 10$. Each setting of the network structure parameter P was replicated 10 times. Error bars represent $\pm 95\%$ CI.




Figure 3: Sample degree distributions for the small world network structures used in this model. Rewiring probabilities (P) are shown and match those that were tested in figure 2. Simulations were run with $N = 25,000$ and $k = 10$. Sample networks show the structures with 250 vertices. Note that a new network was generated for each of the 64,000 simulations.

All individuals were equally susceptible to contracting the SARS-CoV-2 virus from an infectious neighbor. The transmission probability (T) from an infectious individual to a susceptible neighbor on a single day was determined using the following relationship (Hartvigsen et al., 2007).

$$T = 1 - \left(1 - \frac{R_0}{k}\right)^{1/D_I} \quad (1)$$

where R_0 is the average number of secondary infections caused by an infectious individual in a fully susceptible neighborhood, k is the mean degree of the network, and D_I is the number of days an individual is infectious (Walsh et al., 2020) (see table 1). In this model we tested the effects of using R_0 values of 2.5 and 5.0. This relationship for T results in infectious individuals, on average, infecting R_0 susceptible neighbors in a completely susceptible neighborhood. However, as the infection spreads the realized spread rate decreases as the number of susceptible neighbors of infectious individuals decreases. In the event that a susceptible but vaccinated individual is chosen for infection by an infectious neighbor the probability that they become infected is determined by the efficacy level, calculated using equations 2 (see below). With time vaccinated individuals become less susceptible to infection (see Figure 4).

Table 1: **Parameter settings for simulations.** This table contains the different values tested, resulting in a total of 64,000 simulations. The percent of the population vaccinated daily is an upper limit since only S, E, and R individuals could be vaccinated. Maximum efficacy refers to the probability that a vaccinated person is protected from getting infected 21 days after receiving the vaccine.

Parameter	Settings
N	25,000
R_0	2.5, 5.0
Initial number E	3
Initial number I	3
Days E (D_E)	3
Days I (D_I)	10
Average number of neighbors (k)	10
Network rewiring probability (P)	0.004, 0.01, 0.03, 0.1, 0.5
Vaccination strategies (VS)	random, high degree
% vaccinated day ⁻¹ (% Vacc/Day)	0, 0.3%, 0.6%, 0.9%, 1.2%
Number of doses individuals received (ND)	1, 2
Maximum efficacy (probability) of dose #1 ($V_{max,1}$)	0.4, 0.45, 0.5, 0.55, 0.6, 0.65, 0.7, 0.75
Maximum efficacy (probability) of dose #2 ($V_{max,2}$)	0.75, 0.80, 0.85, 0.9
Number replicates	10




Figure 4: The efficacy of vaccines tested (black lines) when administered on day 1. Efficacy in this model is the probability that the individual will not become infected when challenged by an infectious neighbor. We assume that efficacies increase sigmoidally such that it takes time for the immune system to respond (equation 2). The estimated values of efficacies for four vaccines (colored) are shown in comparison to those tested in the model (black lines). The Johnson & Johnson vaccine (JJ) required only one dose and exhibits 72% efficacy. The remaining reference and tested vaccines were administered 21 days after receiving the first vaccine dose (vertical dashed line). Note AZ represents the AstraZenca vaccine.

Assessing how R_0 affects infection rates in the absence of vaccination

Disease agents, like SARS-CoV-2, typically spread through populations at different rates (see Prada et al., 2022). Although difficult to estimate, the parameter R_0 is used to describe the approximate number of secondary infections that a single infectious individual would cause in an otherwise naive population. In a differential equation model with a fully connected population an R_0 value of 1.0 would lead to a sustained number of infectious individuals while values greater than one lead to an epidemic. This is not true in a realistically-structured network population, as explored in this paper, which requires R_0 values greater than about 1.2 for an epidemic to emerge. This, however, is still highly dependent on the structure of the network (figure 5). As a network becomes more randomly connected (increasing values of P) both the clustering coefficient and the average path length decrease, allowing the pathogen to more quickly and widely spread through a population.




Figure 5: The size of the epidemic (number of individuals infected) is influenced by both R_0 and network structure (P). Large epidemics are more likely to occur with larger values of R_0 . On relatively regular networks ($P < 0.03$), epidemics only occur when R_0 is well above 1.0. The model was run with $N = 25,000$, $k = 10$, and no vaccination. The blue and red bars represent the R_0 values tested (2.5 and 5.0, respectively). Error bars represent $\pm 95\%$ confidence intervals.

Implementing vaccinations

We tested the effectiveness of vaccines that exhibit different levels of efficacy, ranging from 40% to 75% protection for the first dose and from 75% to 90% with the second dose (see table 1). Efficacy levels of both doses are assumed to increase sigmoidally, following equations 2. This approximates evidence that, for instance, the BNT162b2 vaccine (BioNTech/Pfizer) efficacy, compared to a placebo control, may not be observed until 12 days after being administered (Polack et al., 2020; Dagan et al., 2021). This is in contrast to recent work by Saad-Roy et al. (2021) who used an asymptotic response function with a more rapid response in individual immunity. In the equations, $E_{1,i}$ and $E_{2,j}$ represent efficacies for the first and second dose of the vaccine on days i (first dose) and j (second dose), respectively.

$$\begin{aligned} E_{1,i} &= \frac{V_{max,1}}{\left(1 + e^{\frac{(\frac{a}{2}-i)}{b}}\right)} \\ E_{2,j} &= E_{1,a} + \frac{V_{max,2} - V_{max,1}}{\left(1 + e^{\frac{(\frac{a}{2}-j)}{b}}\right)} \end{aligned} \tag{2}$$

The second dose was administered on the 22nd day after the individual received the first dose (parameter $a = 21$ days). Additionally, the rate parameter was set to $b = 1.75$, and $V_{max,k}$ represents the maximum efficacy for vaccine doses $k = 1$ and $k = 2$ (table 1). The relationships for these efficacies are shown in figure 4 where values are tested for $0.4 \leq V_{max,1} \leq 0.75$ and $0.75 \leq V_{max,2} \leq 0.9$. The modeled responses for the four reference vaccines also are included.

We also tested two different vaccination strategies. Both strategies select individuals from the S, E, or R classes that have not previously been vaccinated (see figure 1). The random strategy targets individuals with equal probabilities. The high degree strategy preferentially vaccinates individuals based on their degree (from highest to lowest).

4 Results

Model dynamics, using the tested parameter values in table 1, consistently exhibited an epidemic curve with a sigmoidally-shaped number of recovered individuals over time (an example is shown in figure 6). Of the 25,000 individuals, more individuals became infected on average when exposed to the more infectious strain ($R_0 = 2.5$ yielded 8,428 infected individuals while $R_0 = 5.0$ yielded 20,590 individuals, on average; $F = 37,050$; $df = 1, 63,998$; $p < 0.001$). Vaccination greatly reduced the number infected, with fewer subjects becoming infected with higher levels of vaccination rates and higher vaccine efficacies.




Figure 6: A sample simulation of a SARS-CoV-2 epidemic in a municipality with 25,000 individuals. Shown are the number of individuals that were susceptible (S), exposed (E), infectious (I), recovered (R), and the number of individuals vaccinated once (V1) and twice (V2). Random individuals were vaccinated with a first dose at a rate of 0.3% per day. These individuals were then given a second dose 21 days later. The simulation ended when there were no remaining infected individuals (E or I). For this simulation $R_0 = 5.0$, $k = 10$, $P = 0.01$, $V_{max,1} = 0.6$, and $V_{max,2} = 0.9$. In the end 93.5% of the population became infected.

The number of individuals infected depended most on three factors: the structure of the network (P), the percentage of the population vaccinated daily (% Vacc/Day), and the reproductive rate of the virus (R_0) (see Table 2). Additionally, these three factors, along with their interaction, were the most important factors in determining the response of the other three important response variables, including the duration of the epidemic, the number of individuals infectious at the epidemic peak, and day of the epidemic peak (Table 2). Therefore, the results strongly suggest that two factors that we can control, the structure of the interaction network and the rate at which individuals become vaccinated, play a large role in determining the extent of an epidemic.

Table 2: **The percent sums of squares for the four response variables.** The dominant factors influencing these responses were network structure (P), proportion of the population vaccinated per day (% Vacc/Day), R_0 , and their three-way interaction (see figure 7) Note that the percentages of the variance explained are from the full, seven-factor ANOVAs completed for each effect. The greatest contributions to the overall effect are in bold text.

Response Variable	P	% Vacc/Day	R_0	$P \times \% \text{ Vacc/Day} \times R_0$	Total
Number Infected	20.0	19.8	36.7	4.9	81.4
Duration	19.6	6.2	2.2	22.4	50.4
Maximum Number Infectious	45.9	5.1	32.5	0.9	84.4
Day Maximum Infectious	9.7	13.4	1.7	18.8	43.6

Figure 7 provides a summary of the extent of how these three factors interacted to affect the number of individuals that became infected, epidemic duration, and the size and timing of the epidemic peaks (see effect

sizes in table 2). The number of individuals becoming infected was most affected by the virus' reproductive number (R_0). Interestingly, the vaccination rates were quite effective with an $R_0 = 2.5$ (upper-left panel, Figure 7). However, with an $R_0 = 5.0$ the virus was much more aggressive, especially at larger values of P (greater mixing with shorter average path lengths), despite even high rates of vaccination (upper right graph of figure 7).

The duration of the epidemic was longest with low R_0 and no vaccination, as the virus agent made its way through nearly the entire population (second row panels in Figure 7). However, vaccination generally decreased the duration dramatically. The shortest duration occurred with $R_0 = 5.0$. Interestingly, at $R_0 = 5.0$ and relatively high network rewiring values ($P \geq 0.03$), increasing the rate of vaccination led to small *increases* in the duration of the epidemic. Duration, therefore, exhibited a complex response where short epidemic duration is not necessarily an indicator of successful disease containment.

The size of the epidemic peak, which indicates the potential number of individuals simultaneously seeking health care services, was highest with large R_0 (third row panels in figure 7). For both levels of R_0 increasing vaccination rates decreased the epidemic peaks while larger values of P (greater randomization of connections) led to increase epidemic sizes.

The timing of the epidemic peak also is important for health care providers as they prepare for the peak number of infected individuals to enter the health care system. Without vaccination on regularly structured networks led to peaks that occurred quite late in the epidemics (fourth row panels in figure 7). This, however, is deceptive since those peaks were quite small. Also, this only occurred with $R_0 = 2.5$, not with the faster spreading virus. We see that the peak occurred soon into the epidemic with vaccination and with the faster spreading virus ($R_0 = 5.0$). This is particularly true for the faster spreading virus in a population that is more randomly structured (higher values of P).

It is made available under a [CC-BY-NC-ND 4.0 International license](https://creativecommons.org/licenses/by-nc-nd/4.0/).




Figure 7: Three-way interactions are shown for the four response variables (horizontally-paired graphs). These factors include network structure (P, see figure 3), percent vaccinated per day (% Vacc/Day), and R_0 . The interaction terms are all highly significant (see table 2). For all simulations in this figure, vaccinated individuals received two doses. Error bars represent $\pm 95\%$ confidence intervals and are present, but small, on most bars.

4.1 The Effect of Different Vaccines

Not surprisingly, the more effective vaccines resulted in fewer individuals becoming infected (figure 8). More interestingly, administering a second dose resulted in little additional reduction in infections. This is likely due to the epidemic being quelled by the first vaccine and the virus having moved through the population by the time the second vaccine was able to take full effect (a total of 42 days after being administered). There was no significant interaction for the effect of administering either one or two vaccine doses on the number of individuals getting infected (figure 8; $F = 0.005$; $df = 21, 63,968$; $p = 1.0$).




Figure 8: The number of individuals becoming infected by the variant with $R_0 = 2.5$ when receiving vaccines with different efficacies. Increasing the efficacy of the first dose reduces infections ($F = 6.6 \times 10^{10}$; $df = 7, 63,968$; $p < 0.001$) while increasing the efficacy of the second dose has little effect, although it is statistically significant ($F = 3.9 \times 10^9$; $df = 3, 63,968$; $p < 0.001$). There is no interaction between these factors ($F = 9.8 \times 10^6$; $df = 21, 63,968$; $p = 1.0$). Error bars represent $\pm 95\%$ confidence intervals. Dashed, horizontal reference lines are at the lowest and highest means for clarity.

At a finer scale our model allows us to assess the efficacy of different vaccines (see figure 4) as well as the efficacy of individuals receiving zero, one, or two vaccine doses. The tested vaccines had a wide range of efficacies but the effect of different vaccines on epidemic size was relatively small. Additionally, the first vaccine dose accounted for twenty times the effect of adding the second dose, on average. Therefore, these results support that individuals should receive at least a single vaccine dose, even if the vaccine has a probability of 0.4 of protecting a person against infection.




Figure 9: The three-way interaction between the number of vaccine doses individuals received (one versus two), the percent of the population vaccinated per day (% Vacc./Day), and network structure (P) on the total number of individuals that got infected. These simulations represent the average for $R_0 = 2.5$ and 5.0 . Each of the individual factors was significant, with network structure and number of doses per day being the most important factors. Note that the numerical differences between one and two doses without vaccination are not statistically different (e.g., for the rewiring parameter of $P = 0.004$; $p > 0.999$, Tukey HSD). Error bars represent $\pm 95\%$ confidence intervals.

The Number of Individuals Infected Depended on Percent Vaccinated Daily, Vaccine Efficacy, and the Number of Doses Administered

Vaccination reduced the number of infected individuals, with more effective vaccines resulting in fewer cases (Figure 10). This effect was stronger in treatments with subjects receiving only a single dose (left graph, Figure 10). However, when individuals received a second dose fewer individuals were infected but the differences among the efficacies of the first doses were reduced (right graph, Figure 10).




Figure 10: Number of infected individuals versus the vaccine efficacy when one (left panel) and two (right) vaccine doses were administered. The differences among the vaccine efficacies were quite important if individuals received only one dose but if individuals received two doses the differences were reduced. Note that these results average the response of individuals to the differences among the second dose. Error bars represent $\pm 95\%$ confidence intervals.

The Maximum Number of Infected Individuals Depended on Vaccination, Network Structure, and R_0

As stated above the maximum number of individuals infected at the peak of the epidemic is critically important for health care service providers during an epidemic. Not surprisingly most individuals are infected without vaccination (Figure 11). Additionally, the maximum number of individuals infected at the peak is about twice as high with $R_0 = 5.0$ compared to $R_0 = 2.5$. However, when high rates of vaccination are implemented (two doses of vaccines with efficacies of $V_{max,1} = 0.75$ and $V_{max,2} = 0.9$) the number becoming infected with $R_0 = 2.5$ was found to be quite low. However, a strain of virus with an $R_0 = 5.0$ is able to break out quickly and cause widespread infections, particularly with well mixed populations ($P \geq 0.03$).




Figure 11: The maximum number of individuals infectious at the epidemic peak is sensitive to the viral reproduction rate (R_0). Without vaccination (left panel) the peaks increase in severity with increasing network connectivity (P), with peaks approximately doubling in height as R_0 increases from 2.5 to 5.0. With high rates of vaccination ($1.2\% \text{ day}^{-1}$) and high vaccine efficacy ($V_{max,1} = 0.75$, $V_{max,2} = 0.9$) the peaks are much lower with $R_0 = 2.5$ (right panel). However, as seen in figure 9, when $R_0 = 5.0$ even high vaccination rates fail to contain the epidemic peaks when the network connectivity is high (right panel). Error bars represent $\pm 95\%$ confidence intervals.

Vaccination Strategy and Network Structure Affected the Number of Individuals Infected

The two tested strategies differed significantly with preferential vaccination of more connected individuals (high degree) outperforming a random strategy, on average ($F = 4,932$; $df = 1, 5,040$; $p < 0.001$; see figure 12). Not surprisingly, the vaccination strategy interacted significantly with the structure of the network ($F = 1,435$; $df = 3, 5,040$; $p < 0.001$) because with $P > 0.0$ led to individuals with relatively high degrees that were then selected for vaccination, functionally reducing more edges. As can be seen in figure 3, the opportunity to preferentially vaccinate individuals of higher degree increases as the degree distributions broaden. For simulations with $R_0 = 2.5$ differences between the vaccination strategies was seen only with greater randomness in the network structure ($P \geq 0.1$).




Figure 12: The number of individuals getting infected was sensitive to vaccination strategies but only under certain circumstances. With an ($R_0 = 2.5$) the hub (high degree) vaccination strategy was noticeably more effective as the degree distribution broadened (large P). However, this strategy had little effect on controlling the epidemic when $R_0 = 5.0$. Interestingly, the hub strategy was more effective on more regular networks when $R_0 = 5.0$ ($P \leq 0.03$). The data here are from simulations with only the most effective vaccines administered ($V_{max,1} = 0.75$, $V_{max,2} = 0.9$). Error bars represent $\pm 95\%$ confidence intervals.

5 Discussion

This paper describes the dynamics of simulated SARS-CoV-2 spreading through a network population of 25,000 individuals. We test the effects of employing one or two doses of vaccines with different efficacies, and administered at different rates, on reducing the size of the epidemic. We also investigate the effect of different small-world network structures on epidemic development, from a nearly regular network to networks approximating a type of random structure while maintain a constant number of edges connecting individuals.

Our model yields dynamics that follow a standard SEIR curve, even when vaccinations were administered (see figure 6). Since the population is limited to just 25,000 individuals the epidemics that developed only last up to approximately six months. The benefit of this individual-based model is that we're able to assess various factors on the number of individuals infected, epidemic duration, and the timing and size of the epidemic peak. This networked population shows that this disease agent is capable of spreading to a majority of individuals with and without interventions (see top row, figure 7).

Overall, the tested values for the basic reproductive rate of the virus ($R_0 = 2.5$ or 5.0) represent a relatively conservative range for the early part of the original 2020 epidemic, with median estimates across different countries ranging from 3.5 to 5.9(Ke et al., 2021). Our tested values resulted in different rates and extents of epidemic spread.

Additionally, we found that network structure and vaccination rate were quite important in affecting epidemic size and that they interacted statistically with R_0 . These significant effects were seen in the number of individuals infected, epidemic duration, and epidemic peak size and peak timing (see Table 2 and figure 7). These response variables are of great concern during epidemics for general health concerns but also for health systems and providers because of the potential of high patient demand to become overwhelming for service providers. Other approaches have been investigated that also would help to reduce epidemic effects, such as increasing primary health care interventions (Huang et al., 2024), but these were not investigated.

We were able to test the effect of an array of different vaccines which overlapped with known vaccine efficacies. These were provided in either one or two doses, which resulted in statistically different levels of

efficacy in protecting individuals. Our model assumes that the vaccines are, at best, only 90% effective at preventing a person from becoming infectious themselves (VE_2), assuming they come into contact with an infectious neighbor. Although the effect of different vaccines was significant the effect is relatively small, compared to the difference between simply vaccinating and not vaccinating individuals. There is evidence, however, that vaccinated individuals became infected early in the original COVID-19 epidemic (with the early Delta variant, B.1.617.2), a process referred to as “breakthrough infections,” and that even some of those individuals could become infectious (CDC, 2021*b*). This effect was similar to the effect in this model of vaccinated individuals not gaining protection and, therefore, becoming infected and infectious.

The model suggests that, for the total number of infections, the structure of the network is similar in importance to the proportion of the population getting vaccinated. Therefore, efforts to reduce the spread of the virus should include the sharing of information about connectivity in social networks as well as the importance of getting the latest vaccines. Additionally, who receive the vaccines is important, as was seen in the difference between random and degree-based vaccination strategies, with the latter being significantly more effective.

The model does not investigate the effect of social distancing or quarantining of exposed/infectious individuals, although these, and other, non-pharmaceutical interventions have been found to be helpful in reducing the size and spread rate of epidemics (Ferguson et al., 2020; Hartvigsen, 2021; Auranen et al., 2023). There appears to remain some controversy over the two meter social distancing rule that many countries adopted to minimize transmission of the virus between individuals. However, there is support that some level of social distancing does reduce transmission rate (Chu et al., 2020).

As the network structure is changed from regular to more random (larger values of the rewiring parameter P) both the average path length and the clustering coefficient decrease so that infected individuals will more likely have susceptible neighbors allowing the disease agent to spread further through the population (top row of figure 7).

As mentioned, the strategy used to pick individuals to get vaccinated is important. We chose to investigate choosing either individuals randomly or preferentially based on degree (hub vaccination strategy). The latter strategy was significantly more effective, which has been found in many other studies. However, we also found that vaccination strategy interacts significantly with network structure and viral basic reproductive number (R_0) (figure 12).

Interestingly, the duration of epidemics increased with increasing vaccination. This can be explained by the increase in path lengths among the susceptible individuals within the network. Using this model we were able to assess this and found that the high-degree vaccination strategy was more effective at reducing the duration of epidemics. This also was true for tests when only one dose was administered, although more individuals were infected and the duration of the epidemics were somewhat longer (figure 7).

Our model assumes that all individuals are equally susceptible to SARS-CoV-2 infection and that there were no negative outcomes from vaccination. We also ignore any acute or chronic effects due to SARS-CoV-2 infection. Our model does not allow for breakthrough infections (infections occurring in vaccinated individuals), although the number of such occurrences in our population of 25,000 would be low (see Kelly et al., 2022). However, vaccinations in our model never provide 100% coverage, either (see figure 4). Finally, this model does not address the ability of SARS-CoV-2 to evolve or for people to change their behavior that likely occurs as an epidemic develops (see Traulsen et al., 2023).

6 Data Analysis

All analyses and model runs were completed using R (R Core Team, 2024). Networks were constructed using the `igraph` package (igraph.org).

7 Acknowledgements

The authors would like to thank SUNY Geneseo’s Sponsored Programs Office. We also would like to thank Marisa Presutto, Grace Maley, and Christopher Leary. Finally, thanks to the R Core Team (2024) and RStudio (2020) developers.

References

- Auranen, K., M. Shubin, E. Erra, S. Isosomppi, J. Kontto, T. Leino, and T. Lukkarinen. 2023. Efficacy and effectiveness of case isolation and quarantine during a growing phase of the covid-19 epidemic in finland. *Scientific Reports*, **13**:298. URL <https://doi.org/10.1038/s41598-022-27227-2>.
- Banerjee, A., L. Pasea, S. Harris, A. Gonzalez-Izquierdo, A. Torralbo, L. Shallcross, M. Noursadeghi, D. Pilla, N. Sebire, C. Holmes, C. Pagel, W. K. Wong, C. Langenberg, B. Williams, S. Denaxas, and H. Hemingway. 2020. Estimating excess 1-year mortality associated with the COVID-19 pandemic according to underlying conditions and age: a population-based cohort study. *The Lancet*, **395**:1715–1725.
- CDC. 2021a. COVID data tracker (accessed October 13, 2023). URL <https://covid.cdc.gov/covid-data-tracker/>.
- CDC. 2021b. Delta variant. <https://www.cdc.gov/coronavirus/2019-ncov/variants/delta-variant.html>.
- Chu, D. K., E. A. Akl, S. Duda, K. Solo, S. Yaacoub, H. J. Schünemann, et al. 2020. Physical distancing, face masks, and eye protection to prevent person-to-person transmission of SARS-CoV-2 and COVID-19: a systematic review and meta-analysis. *Lancet*, **395**:1973–1987. URL [https://www.thelancet.com/journals/lancet/article/PIIS0140-6736\(20\)31142-9/fulltext](https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(20)31142-9/fulltext). Epub 2020 Jun 1.
- Dagan, N., N. Barda, E. Kepten, O. Miron, S. Perchik, M. A. Katz, M. A. Hernán, M. Lipsitch, B. Reis, and R. D. Balicer. 2021. Bnt162b2 mRNA covid-19 vaccine in a nationwide mass vaccination setting. *New England Journal of Medicine*, **384**:1412–1423. URL <https://doi.org/10.1056/NEJMoa2101765>.
- de Gier, B., L. van Asten, T. M. Boere, A. van Roon, C. van Roekel, J. Pijpers, C. H. H. van Werkhoven, C. van den Ende, S. J. M. Hahné, H. E. de Melker, M. J. Knol, and S. van den Hof. 2023. Effect of COVID-19 vaccination on mortality by COVID-19 and on mortality by other causes, the Netherlands, January 2021-January 2022. *Vaccine*, **41**:4488–4496.
- El Sahly, H. M., L. R. Baden, B. Essink, S. Doblecki-Lewis, J. M. Martin, E. J. Anderson, T. B. Campbell, J. Clark, L. A. Jackson, C. J. Fichtenbaum, M. Zervos, B. Rankin, F. Eder, G. Feldman, C. Kennelly, L. Han-Conrad, M. Levin, K. M. Neuzil, L. Corey, P. Gilbert, H. Janes, D. Follmann, M. Marovich, L. Polakowski, J. R. Mascola, J. E. Ledgerwood, B. S. Graham, A. August, H. Clouting, W. Deng, S. Han, B. Leav, D. Manzo, R. Pajon, F. Schödel, J. E. Tomassini, H. Zhou, and J. Miller. 2021. Efficacy of the mRNA-1273 SARS-CoV-2 vaccine at completion of blinded phase. *New England Journal of Medicine*, **385**:1774–1785. URL <https://doi.org/10.1056/NEJMoa2113017>. PMID: 34551225.
- Ferguson, N. M., D. Laydon, G. Nedjati-Gilani, N. Imai, K. Ainslie, M. Baguelin, S. Bhatia, A. Boonyasiri, Z. Cucunubá, G. Cuomo-Dannenburg, et al. 2020. Report 9: Impact of non-pharmaceutical interventions (NPIs) to reduce COVID19 mortality and healthcare demand, volume 16. Imperial College London London.
- Gandon, S., M. Mackinnon, S. Nee, and A. Read. 2001. Imperfect vaccines and the evolution of pathogen virulence. *Nature*, **414**:751–756.
- Hartvigsen, G. 2021. Network assessment and modeling the management of an epidemic on a college campus with testing, contact tracing, and masking. *PLoS ONE*, **16**(9). URL <https://www.medrxiv.org/content/early/2021/04/09/2021.04.06.21255015>.

- Hartvigsen, G., J. Dresch, A. Zielinski, A. Macula, and C. Leary. 2007. Network structure, and vaccination strategy and effort interact to affect the dynamics of influenza epidemics. *Journal of Theoretical Biology*, **246**:205 – 213.
- Huang, J., Y. Qian, Y. Yan, H. Liang, and L. Zhao. 2024. Addressing hospital overwhelm during the COVID-19 pandemic by using a primary health care-based integrated health system: Modeling study. *JMIR Medical Informatics*, **12**:e54355.
- IHME. 2021. COVID-19 vaccine efficacy summary. Institute for Health Metrics and Evaluation. URL <http://www.healthdata.org/covid/covid-19-vaccine-efficacy-summary>.
- Ke, R., E. Romero-Severson, S. Sanche, and N. Hengartner. 2021. Estimating the reproductive number R_0 of SARS-CoV-2 in the United States and eight European countries and implications for vaccination. *Journal of Theoretical Biology*, **517**:110621. URL <https://www.sciencedirect.com/science/article/pii/S0022519321000436>.
- Kelly, J. D., S. Leonard, K. J. Hoggatt, W. J. Boscardin, E. N. Lum, T. A. Moss-Vazquez, R. Andino, J. K. Wong, A. Byers, D. M. Bravata, P. C. Tien, and S. Keyhani. 2022. Incidence of severe COVID-19 illness following vaccination and booster with BNT162b2, mRNA-1273, and Ad26.COV2.s vaccines. *JAMA*, **328**:1427–1437. URL <https://doi.org/10.1001/jama.2022.17985>.
- Kundu, R., J. S. Narean, L. Wang, J. Fenn, T. Pillay, N. D. Fernandez, E. Conibear, A. Koycheva, M. Davies, M. Tolosa-Wright, S. Hakki, R. Varro, E. McDermott, S. Hammett, J. Cutajar, R. S. Thwaites, E. Parker, C. Rosadas, M. McClure, R. Tedder, G. P. Taylor, J. Dunning, and A. Lalvani. 2022. Cross-reactive memory T cells associate with protection against SARS-CoV-2 infection in COVID-19 contacts. *Nature Communications*, **13**:80. URL <https://doi.org/10.1038/s41467-021-27674-x>.
- Link-Gelles, R., A. Ciesla, J. Mak, et al. 2024. Early estimates of updated 2023–2024 (monovalent XBB.1.5) COVID-19 vaccine effectiveness against symptomatic SARS-CoV-2 infection attributable to co-circulating Omicron variants among immunocompetent adults – increasing community access to testing program, United States, September 2023–January 2024. *MMWR Morb Mortal Wkly Rep*, **73**:77–83.
- Perkins, T., R. Reiner, Jr., G. España, Q. ten Bosch, A. Verma, K. Liebman, V. Paz-Soldan, J. Elder, A. Morrison, S. Stoddard, U. Kitron, G. Vazquez-Prokopec, T. Scott, and D. Smith. 2019. An agent-based model of dengue virus transmission shows how uncertainty about breakthrough infections influences vaccination impact projections. *PLOS Computational Biology*, **15**:1–32.
- Polack, F., S. Thomas, N. Kitchin, J. Absalon, A. Gurtman, S. Lockhart, J. Pérez, P. M.G., E. Moreira, C. Zerbini, R. Bailey, K. Swanson, S. Roychoudhury, K. Koury, P. Li, W. Kalina, D. Cooper, R. Frenck, L. Hammitt, O. Türeci, H. Nell, A. Schaefer, S. Ünal, D. Tresnan, S. Mather, P. Dormitzer, U. Sahin, K. Jansen, and W. Gruber. 2020. Safety and efficacy of the BNT162b2 mRNA Covid-19 vaccine. *New England Journal of Medicine*, **383**:2603–2615. PMID: 33301246.
- Prada, J. P., L. E. Maag, L. Siegmund, E. Bencurova, C. Liang, E. Koutsilieri, T. Dandekar, and C. Scheller. 2022. Estimation of R_0 for the spread of SARS-CoV-2 in Germany from excess mortality. *Scientific Reports*, **12**:17221. URL <https://doi.org/10.1038/s41598-022-22101-7>.
- R Core Team. 2024. R: A Language and Environment for Statistical Computing. R Foundation for Statistical Computing, Vienna, Austria. URL <https://www.R-project.org/>.
- Rahmani, K., R. Shavaleh, M. Forouhi, H. F. Disfani, M. Kamandi, R. K. Oskooi, M. Foogerdi, M. Soltani, M. Rahchamani, M. Mohaddespour, and M. Dianatinasab. 2022. The effectiveness of COVID-19 vaccines in reducing the incidence, hospitalization, and mortality from COVID-19: A systematic review and meta-analysis.

- RStudio Team. 2020. RStudio: Integrated Development Environment for R. RStudio, PBC., Boston, MA. URL <http://www.rstudio.com/>.
- Saad-Roy, C., S. Morris, C. Metcalf, M. Mina, R. Baker, J. Farrar, E. Holmes, O. Pybus, A. Graham, S. Levin, B. Grenfell, and C. Wagner. 2021. Epidemiological and evolutionary considerations of SARS-CoV-2 vaccine dosing regimes. *Science*, **372**:363–370. URL <https://science.sciencemag.org/content/372/6540/363>.
- Steinert, J., H. Sternberg, H. Prince, B. Fasolo, M. Galizzi, T. Bütthe, and G. Veltri. 2022. Covid-19 vaccine hesitancy in eight European countries: Prevalence, determinants, and heterogeneity. *Science Advances*, **8**:eabm9825.
- Traulsen, A., S. A. Levin, and C. M. Saad-Roy. 2023. Individual costs and societal benefits of interventions during the COVID-19 pandemic. *Proceedings of the National Academy of Sciences*, **120**:e2303546120. URL <https://www.pnas.org/doi/abs/10.1073/pnas.2303546120>.
- Walsh, K., S. Spillane, L. Comber, K. Cardwell, P. Harrington, J. Connell, C. Teljeur, N. Broderick, C. de Gascun, S. Smith, M. Ryan, and M. O’Neill. 2020. The duration of infectiousness of individuals infected with SARS-CoV-2. *The Journal of infection*, **81**:847–856.
- Watts, D. and S. Strogatz. 1998. Collective dynamics of “small-world” networks. *Nature*, **393**:440 – 442.
- WHO. 2020. Impact of COVID-19 on people’s livelihoods, their health and our food systems. Joint statement by ILO, FAO, IFAD and WHO. URL <https://www.who.int/news/item/13-10-2020-impact-of-covid-19-on-people’s-livelihoods-their-health-and-our-food-systems>.
- Yonker, L., A. Neilan, Y. Bartsch, A. Patel, J. Regan, P. Arya, E. Gootkind, G. Park, M. Hardcastle, A. St John, L. Appleman, M. Chiu, A. Fialkowski, D. De la Flor, R. Lima, E. Bordt, L. Yockey, P. D’Avino, S. Fischinger, J. Shui, P. Lerou, J. Bonventre, X. Yu, E. Ryan, I. Bassett, D. Irimia, A. Edlow, G. Alter, J. Li, and A. Fasano. 2020. Pediatric severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2): Clinical presentation, infectivity, and immune responses. *The Journal of Pediatrics*, **227**:45–52.e5.